In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 1, 2013, Pages 59-66

  Walker, Matthew D ^a   Dinelle, Katherine ^a   Kornelsen, Rick ^a   McCormick, Siobhan ^a   Mah, Chenoa ^a   Holden, James E ^b   Farrer, Matthew J ^a   Stoessl, A Jon ^a   Sossi, Vesna ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

6 OHDA lesion; dopamine synthesis; FDOPA; Parkinson's disease; PET

Indexed keywords

6 FLUORODOPA F 18; BENSERAZIDE; DOPAMINE; ENTACAPONE; LEVODOPA; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; CEREBELLUM; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG UPTAKE; FUNCTIONAL NEUROIMAGING; HALF LIFE TIME; IMAGE ANALYSIS; IN VIVO STUDY; MALE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; DOPAMINE; FLUORINE RADIOISOTOPES; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84871923385     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.120     Document Type: Article

References (40)

1. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humansstudied with positron emission tomography. Ann Neurol 1989; 26: 535-542. (Pubitemid 19247230)
2. Gjedde A, Reith J, Dyve S, Leger G, Guttman M, Diksic M et al Dopa decarboxylaseactivity of the living human brain. Proc Natl Acad Sci USA 1991; 88: 2721-2725. (Pubitemid 21916490)
3. Sossi V, Doudet DJ, Holden JE. A reversible tracer analysis approach to the studyof effective dopamine turnover. J Cereb Blood Flow Metab 2001; 21: 469-476. (Pubitemid 32298893)
4. Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a reviewof clinical findings and modeling approaches. Neuroscientist 2009; 15: 635-650.
5. Sossi V, Fuente-Fernandez R, Nandhagopal R, Schulzer M, McKenzie J, Ruth TJ et alDopamine turnover increases in asymptomatic LRRK2 mutations carriers. MovDisord 2010; 25: 2717-2723.
6. Barrio JR, Huang SC, Melega WP, Yu DC, Hoffman JM, Schneider JS et al 6-[F-18]Fluoro-L-Dopa probes dopamine turnover rates in central dopaminergicstructures. J Neurosci Res 1990; 27: 487-493.
7. Doudet DJ, Chan GLY, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ. Effects ofcatechol-O-methyltransferase inhibition on the rates of uptake and reversibility of6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology1997; 36: 363-371. (Pubitemid 27198697)
8. Doudet DJ, Chan GLY, Holden JE, Mcgeer EG, Aigner TA, Wyatt RJ et al 6-[F-18]fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-inducedparkinsonism in monkeys. Synapse 1998; 29: 225-232. (Pubitemid 28267931)
9. Kyono K, Takashima T, Katayama Y, Kawasaki T, Zochi R, Gouda M et al Use of[18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally6-OHDA-lesioned rats. EJNMMI Res 2011; 1: 25.
10. Huang SC, Yu DC, Barrio JR, Grafton S, Melega WP, Hoffman JM et al Kinetics andmodeling of L-6-[F-18] fluoro-dopa in human positron emission tomographicstudies. J Cereb Blood Flow Metab 1991; 11: 898-913.
11. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constantsfrom multiple-time uptake data-generalizations. J Cereb Blood Flow Metab 1985;5: 584-590. (Pubitemid 16218234)
12. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volumeratios without blood sampling from graphical analysis of PET data. J Cereb BloodFlow Metab 1996; 16: 834-840. (Pubitemid 26292051)
13. Holden JE, Doudet D, Endres CJ, Chan GLY, Morrison KS, Vingerhoets FJG et alGraphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-Omethyltransferase.J Nucl Med 1997; 38: 1568-1574. (Pubitemid 27443957)
14. Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressiveneurodegeneration or endogenous compensation in an animal model of parkinson'sdisease produced by decreasing doses of alpha-synuclein. Plos One 2011; 6.
15. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascadeleading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration.J Neurosci 2010; 30: 8083-8095.
16. Ito Y, Fujita M, Shimada S, Watanabe Y, Okada T, Kusuoka H et al Comparisonbetween the decrease of dopamine transporter and that of L-DOPA uptake fordetection of early to advanced stage of Parkinson's disease in animal models.Synapse 1999; 31: 178-185. (Pubitemid 29063287)
17. Forsback S, Niemi R, Marjamaki P, Eskola O, Bergman J, Gronroos T et al Uptake of6-[F-18]fluoro-L-dopa and [F-18]CFT reflect nigral neuronal loss in a rat model ofParkinson's disease. Synapse 2004; 51: 119-127. (Pubitemid 38018794)
18. Sharma SK, El ReFaey H, Ebadi M. Complex-1 activity and F-18-DOPA uptake ingenetically engineered mouse model of Parkinson's disease and the neuroprotectiverole of coenzyme Q(10). Brain Res Bull 2006; 70: 22-32. (Pubitemid 43783378)
19. Cumming P, Boyes BE, Martin WRW, Adam M, Grierson J, Ruth T et al Themetabolism of [F-18] 6-Fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat.J Neurochem 1987; 48: 601-608. (Pubitemid 17005174)
20. Reith J, Dyve S, Kuwabara H, Guttman M, Diksic M, Gjedde A. Blood-brain transferand metabolism of 6-[F-18]Fluoro-L-Dopa in rat. J Cereb Blood Flow Metab 1990;10: 707-719. (Pubitemid 20260952)
21. DeJesus OT, Haaparanta M, Solin O, Nickles RJ. 6-FluoroDOPA metabolism in ratstriatum: time course of extracellular metabolites. Brain Res 2000; 877: 31-36.
22. Pauwels T, Dethy S, Goldman S, Monclus M, Luxen A. Effect of catechol-O-methyltransferase inhibition on peripheral and central metabolism of 6-[F-18]Fluoro-LDopa.Eur J Pharmacol 1994; 257: 53-58. (Pubitemid 24178550)
23. Okada M, Nakao R, Hosoi R, Zhang MR, Fukumura T, Suzuki K et al Microdialysiswith radiometric monitoring of L-[beta-(11)C]DOPA to assess dopaminergicmetabolism: effect of inhibitors of L-amino acid decarboxylase, monoamineoxidase, and catechol-O-methyltransferase on rat striatal dialysate. J Cereb BloodFlow Metab 2011; 31: 124-131.
24. Stout DB, Huang SC, Namavari M, Satyamurthy N, Yee RE, Barrio Jr. Distributionvolume of 3-O-methyl-6-[F-18]DOPA in rat brain. J Cereb Blood Flow Metab 2000;20: 1717-1724.
25. Baker H, Abate C, Szabo A, Joh TH. Species-specific distribution of aromatic Lamino-acid decarboxylase in the rodent adrenal-gland, cerebellum, and olfactorybulb.J Comp Neurol 1991; 305: 119-129.
26. Ungerste U. 6-hydroxy-dopamine induced degeneration of central monoamineneurons. Eur J Pharmacol 1968; 5: 107-110.
27. Robinson TE, Whishaw IQ. Normalization of extracellular dopamine in striatumfollowing recovery from a partial unilateral 6-Ohda lesion of the substantia nigra-a microdialysis study in freely moving rats. Brain Res 1988; 450: 209-224.
28. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensationsafter lesions of central dopaminergic-neurons-some clinical and basicimplications. Trends Neurosci 1990; 13: 290-296. (Pubitemid 20193461)
29. Masuo Y, Pelaprat D, Scherman D, Rostene W. [H-3] dihydrotetrabenazine, a newmarker for the visualization of dopaminergic denervation in the rat striatum.Neurosci Lett 1990; 114: 45-50. (Pubitemid 20178265)
30. Sossi V, Holden JE, Topping GJ, Camborde ML, Kornelsen RA, McCormick SE et alIn vivo measurement of density and affinity of the monoamine vesiculartransporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood FlowMetab 2007; 27: 1407-1415. (Pubitemid 46985355)
31. Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopaminemetabolism-a microdialysis study. Brain Res 1992; 587: 241-249.
32. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press:Orlando, FL, USA, 1997.
33. Kelly PH, Iversen SD. Selective 6OHDA-induced destruction of mesolimbicdopamine neurons-abolition of psychostimulant-induced locomotor-activity inrats. Eur J Pharmacol (1976); 40: 45-56.
34. Namavari M, Bishop A, Satyamurthy N, Bida G, Barrio Jr. Regioselectiveradiofluorodestannylation with [F-18] F2 and [F-18] Ch3Coof-a high-yieldsynthesis of 6-[F-18]Fluoro-L-Dopa. Appl Radiat Isot 1992; 43: 989-996.
35. Adam MJ, Jivan S, Huser JM, Lu J. C-11-methylations using C-11-methyl iodide andtetrabutylammonium fluoride. Radiochim Acta 2000; 88: 207-209.
36. Kim JS, Lee JS, Im KC, Kim SJ, Kim SY, Lee DS et al Performance measurement ofthe microPET focus 120 scanner. J Nucl Med 2007; 48: 1527-1535.
37. McLellan CA, Doudet DJ, Brucke T, Aigner TG, Cohen RM. New rapid analysismethod demonstrates differences in 6-(F-18)Fluoro-L-Dopa plasma input curveswith and without carbidopa and in hemi-Mptp lesioned monkeys. Appl Radiat Isot1991; 42: 847-854.
38. Topping GJ, Dinelle K, Kornelsen R, McCormick S, Holden JE, Sossi V. Positronemission tomography kinetic modeling algorithms for small animal dopaminergicsystem imaging. Synapse 2010; 64: 200-208.
39. Sossi V, Holden JE, Fuente-Fernandez R, Ruth TJ, Stoessl AJ. Effect of dopamineloss and the metabolite 3-O-methyl-[F-18]fluoro-dopa on the relation betweenthe F-18-fluorodopa tissue input uptake rate constant K-occ and the [F-18]fluorodopa plasma input uptake rate constant K-i. J Cereb Blood Flow Metab2003; 23: 301-309. (Pubitemid 36307574)
40. Jonkers N, Sarre S, Ebinger G, Michotte Y. Benserazide decreases central AADCactivity, extracellular dopamine levels and levodopa decarboxylation in striatumof the rat. J Neural Transm 2001; 108: 559-570. (Pubitemid 32441871)